Skip to main content

Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.

Publication ,  Journal Article
Patel, MR; Granger, CB
Published in: Drugs Today (Barc)
March 2005

Despite significant advances in the study of myocardial reperfusion, patients with epicardial coronary reperfusion still have adverse clinical outcomes. This is in part due to an inflammatory reaction in the injured tissue. Inflamed myocardial tissue after ischemia and reperfusion releases several cytokines and toxic metabolites that lead to reperfusion injury and cellular apoptosis. Complement activation appears to mediate myocardial damage through both these pathways. Recently, pexelizumab, a novel C5 complement monoclonal antibody fragment, has been developed to prevent the complement-mediated myocardial damage from myocardial ischemia and reperfusion. In animal studies, pexelizumab decreased the amount of myocardial damage with ischemia and reperfusion. Pexelizumab has been studied in phase II and phase III clinical trials involving patients undergoing coronary artery bypass grafting and in patients with acute myocardial infarction as an adjunct to reperfusion therapy. Two large clinical trials are currently underway in coronary artery bypass surgery and acute myocardial infarction patients undergoing primary percutaneous revascularization. This review will cover the pathophysiological role of complement activation with regards to ischemia-reperfusion injury, the novel compound pexelizumab, and both the preclinical and clinical data for pexelizumab use in coronary artery bypass surgery and acute myocardial infarction patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Drugs Today (Barc)

DOI

ISSN

1699-3993

Publication Date

March 2005

Volume

41

Issue

3

Start / End Page

165 / 170

Location

Spain

Related Subject Headings

  • Technology, Pharmaceutical
  • Single-Chain Antibodies
  • Pharmacology & Pharmacy
  • Myocardial Reperfusion Injury
  • Humans
  • Clinical Trials as Topic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • 3214 Pharmacology and pharmaceutical sciences
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, M. R., & Granger, C. B. (2005). Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today (Barc), 41(3), 165–170. https://doi.org/10.1358/dot.2005.41.3.892521
Patel, Manesh R., and Christopher B. Granger. “Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.Drugs Today (Barc) 41, no. 3 (March 2005): 165–70. https://doi.org/10.1358/dot.2005.41.3.892521.
Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today (Barc). 2005 Mar;41(3):165–70.
Patel, Manesh R., and Christopher B. Granger. “Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.Drugs Today (Barc), vol. 41, no. 3, Mar. 2005, pp. 165–70. Pubmed, doi:10.1358/dot.2005.41.3.892521.
Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today (Barc). 2005 Mar;41(3):165–170.

Published In

Drugs Today (Barc)

DOI

ISSN

1699-3993

Publication Date

March 2005

Volume

41

Issue

3

Start / End Page

165 / 170

Location

Spain

Related Subject Headings

  • Technology, Pharmaceutical
  • Single-Chain Antibodies
  • Pharmacology & Pharmacy
  • Myocardial Reperfusion Injury
  • Humans
  • Clinical Trials as Topic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • 3214 Pharmacology and pharmaceutical sciences
  • 3211 Oncology and carcinogenesis